PharmaEssentia
As of the edition of 20 October 2026, PharmaEssentia runs 2 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ropeginterferon alfa-2b | Ends 2033 (computed from the first US licence) | 0 |
| Tirbanibulin | Ends 2038 (patent) | 1 |
A route B row is one company at one target.
Where its trials are
- Digestive system: 1 trials led
- Infections: 1 trials led
- Skin and connective tissue: 1 trials led